Kimball Electronics, Inc.

Fundamentals6.0
Price Action4.0
News Sentiment6.0
AI Rating
5.0

Key Drivers

  • Strong liquidity
  • Thin margins
  • High working capital

AI
AI Summary

5.0

KE is now best viewed as a Medical-led turnaround rather than a broad industrial manufacturer: Medical growth and margin/cash improvement are offsetting Automotive/Industrial कमजोरी, but investors should expect near-term earnings pressure from the Indianapolis buildout and only consider the stock if the market can sustain evidence of multi-quarter revenue stabilization and cash conversion.

MarginImprovement
DemandRisk
Turnaround‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong liquidity
  • Thin margins
  • High working capital

KE appears financially stable and cash-generative, but thin margins, heavy working-capital demands, and a high P/E suggest limited earnings quality despite moderate leverage.

Stable
WeakMargins

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Weak momentum
  • Tentative rebound

KE remains in a short-term downtrend over the last month, but the bounce from $23.41 to $24.60 suggests near-term support is holding while price still needs to reclaim $25.00-$25.80 to confirm a recovery.

downtrend
rebound
Support Level: $23.40
Resistance Level: $25.00-$25.80

Sharp rebound from $23.41 on 2026-05-19 to $24.60 on 2026-05-22 after a recent low

Sentiment & News

6.0

Key News Insights:

  • Mixed Q3
  • Medical Growth
  • Guidance Reaffirmed

Kimball Electronics delivered mixed Q3 results, missing earnings and revenue estimates but posting strong medical sales growth and reaffirming FY2026 guidance with margin expectations at the high end.

earnings
medical

The update is modestly supportive for the stock due to margin confidence and medical segment strength, but the miss on estimates may keep near-term upside limited